South Texas Money Management Ltd. decreased its position in Johnson & Johnson (NYSE:JNJ) by 1.8% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 18,491 shares of the company’s stock after selling 344 shares during the period. South Texas Money Management Ltd.’s holdings in Johnson & Johnson were worth $2,243,000 as of its most recent filing with the SEC.
Other hedge funds also recently bought and sold shares of the company. Riverbridge Partners LLC boosted its stake in Johnson & Johnson by 1.0% in the second quarter. Riverbridge Partners LLC now owns 32,120 shares of the company’s stock worth $3,896,000 after buying an additional 333 shares during the last quarter. TradeLink Capital LLC bought a new stake in Johnson & Johnson during the second quarter worth $233,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Johnson & Johnson by 12.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 974,853 shares of the company’s stock worth $118,250,000 after buying an additional 105,817 shares during the last quarter. Klingenstein Fields & Co. LLC boosted its stake in Johnson & Johnson by 1.9% in the second quarter. Klingenstein Fields & Co. LLC now owns 751,757 shares of the company’s stock worth $91,188,000 after buying an additional 13,726 shares during the last quarter. Finally, St. James Investment Company LLC boosted its stake in Johnson & Johnson by 9.2% in the second quarter. St. James Investment Company LLC now owns 7,299 shares of the company’s stock worth $885,000 after buying an additional 616 shares during the last quarter. 65.32% of the stock is owned by institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.36% on Monday, reaching $118.56. The company had a trading volume of 3,617,756 shares. The stock has a market capitalization of $324.37 billion, a PE ratio of 22.09 and a beta of 0.62. Johnson & Johnson has a 52-week low of $92.58 and a 52-week high of $126.07. The company has a 50 day moving average price of $119.23 and a 200 day moving average price of $116.66.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.06. The firm earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. On average, equities research analysts anticipate that Johnson & Johnson will post $6.69 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd were given a dividend of $0.80 per share. The ex-dividend date was Friday, August 19th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.71%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.15%.
A number of research firms have weighed in on JNJ. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $123.14 price objective for the company in a research report on Monday. Zacks Investment Research cut Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, September 28th. Credit Suisse Group AG reaffirmed a “neutral” rating and set a $123.00 price objective on shares of Johnson & Johnson in a research report on Monday, September 19th. Jefferies Group reduced their price target on Johnson & Johnson from $119.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, September 13th. Finally, Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $120.19.
In other news, CAO Ronald A. Kapusta sold 2,935 shares of the stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the sale, the chief accounting officer now owns 28,660 shares in the company, valued at approximately $3,582,786.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Dominic J. Caruso sold 41,146 shares of the stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. Insiders own 0.11% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.